| Document |
Document Title |
|
WO/2005/121166A1 |
The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences en...
|
|
WO/2005/090404A2 |
The present invention is directed to novel antigens, antibodies and antigen binding fragments thereof, and to immunoassays and kits using these antigens and antibodies. The compositions and methods are useful in the determination of leve...
|
|
WO/2005/087927A1 |
The present invention relates to a method for the production, isolation, and purification of a recombinant protein, more particularly, to a method for isolating and purifying a foreign protein stably using Anti-Freeze Protein (AFP), ther...
|
|
WO/2005/068087A2 |
The invention relates to methods for coating objects with hydrophobins. Provided is a method for providing the surface of an object with a hydrophobin coating, comprising contacting at least a part of an object with a hydrophobin-contain...
|
|
WO/2005/056572A2 |
The present invention provides novel clustered multi-antigenic; constructs having the structure (I) and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, prefe...
|
|
WO/2005/040193A2 |
Synthetic peptides derived from sucrose synthase, and having homology to actin and actin-related proteins, sharing a common motif, useful for causing acting bundling and preventing actin depolymerization. Peptides exhibiting the common m...
|
|
WO/2005/034844A2 |
Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical composit...
|
|
WO/2005/023284A1 |
The present invention relates to the use of a peptide comprising the amino acid sequence F X1 W R C C L I P X2 C R X3 X4 X5 K K F X6 C wherein X1, X3, X4 and X5 are independently any amino acid and wherein X2 and X6 are independently any...
|
|
WO/2005/018575A2 |
The present disclosure relates to the field of cellular tumorigenesis and cancer biology. More specifically, the present disclosure relates to tumorigenesis and cancer in estrogen-responsive cell types, including cell types such as testi...
|
|
WO/2005/016957A1 |
There are disclosed a natural peptide search in which a template reaction with the nucleus of a minute amount of amyloid β-protein having undergone amyloid fibrosis is induced so as to form amyloid fibers, followed by fiber amount incre...
|
|
WO2003082019A9 |
A process for preparing peptides with anti-hypertensive properties and a process for preparing a functional food product comprising peptides with anti-hypertensive properties.
|
|
WO/2005/011607A2 |
The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodim...
|
|
WO/2005/009363A2 |
The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progr...
|
|
WO/2005/009217A2 |
The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progr...
|
|
WO/2005/007680A1 |
Described is a method for the preparation of a mixture of peptides, having an arginine and lysine content of at least 20 w/w%, based on the protein content, from at least one protein source, to a preparation comprising a mixture of argin...
|
|
WO/2004/112572A2 |
This invention relates to the diagnosis and/or monitoring of patients with inflammatory diseases or conditions, e.g., immunologic, hematologic, vascular, or infectious diseases or conditions, by determining levels of complement pathway c...
|
|
WO/2004/110390A2 |
Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic proc...
|
|
WO/2004/093662A2 |
It is to provide a method and a kit for detecting the prognosis of cancer at high accuracy in a simple and rapid manner at low cost. The method is specifically a method for detecting the prognosis of cancer, at least including a step of ...
|
|
WO/2004/083154A1 |
A process for isolating low molecular weight (“LMW”) peptides from tissue in situ comprising the steps: a) homogenizing the tissue; b) mixing the homogenized tissue with an organic solvent to form a fully-wetted slurry; c) standing o...
|
|
WO/2004/078926A2 |
Compounds, compositions and methods for identifying human or other animals having a particular characteristic, by administration of an antigenic marker that elicits a unique antigenic response. Compositions comprise: (a) an antigenic mar...
|
|
WO/2004/065547A2 |
The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibod...
|
|
WO/2004/047762A2 |
The present invention relates generally to cancer treatment, prophylaxis, and detection, and more specifically, to Porimin binding partners and methods for using Porimin as a target for the treatment, prophylaxis and/or detection of canc...
|
|
WO2003031623A9 |
The present invention pertains to peptides derived from fermented cocoa beans and representing cocoa and/or chocolate flavour precursors. In particular, the present invention relates to a process for preparing cocoa and/or chocolate flav...
|
|
WO/2004/042350A2 |
This invention relates to the use of amine, amino acid or amino acid ester mobile phase modifiers in normal phase chromatography to improve the resolution and/or productivity of peptide and lipopeptide purification. This chromatographic ...
|
|
WO/2004/022084A1 |
The present invention relates generally to a method of modulating T cell functional activity by utilising β-amino acid substituted peptides and to agents useful for the same. More particularly, the present invention relates to a method ...
|
|
WO/2004/011486A2 |
The invention concerns a molecule of pharmaceutical interest, preferably a hydrophobic major histocompatibility complex (MHC) ligand soluble in solvents such as DMSO, solubilized in an aqueous medium capable of being injected into a huma...
|
|
WO2003037172A9 |
The present invention relates to peptides and their derivatives which bind to endothelial cells and inhibit their proliferation in in vitro assays, e.g., also referred to herein as endothelial cell binding peptide (ECBP) or ECBP sequence...
|
|
WO/2003/087400A1 |
A kit of parts comprising two or more protein kinase substrate polypeptides, each said substrate polypeptide comprising a specificity conferring portion (which is different for each said kinase substrate polypeptide) and a phosphorylatab...
|
|
WO/2003/085122A2 |
The present invention relates to isolated strains of a Streptomyces spp., which are endophytes of dicotyledonous plants and to methods for selecting such strains. The present invention also relates to compounds having biological activity...
|
|
WO/2003/082197A2 |
The present invention relates to compositions and methods for suppressing an immune response, e.g, by inhibiting class II MHC- mediated activation of T cells. The subject compounds and methods may be used to treat or prevent disorders su...
|
|
WO/2003/059385A2 |
This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compos...
|
|
WO/2003/037266A2 |
Compounds of formula (SEQ ID NO:2) and (SEQ ID NO:3), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, ...
|
|
WO/2003/035675A1 |
The present invention relates to biologically active peptides derived from the neurite outgrowth-promoting domain of laminin-1, i.e. the $g(g)1-chain of laminin-1. These peptides include the decapeptide RDIAEIIKDI and the truncated pepti...
|
|
WO/2003/020749A2 |
The present invention concerns an NCAM (neural cell adhesion molecule) binding compound capable of stimulating NCAM signalling and/or interfering with cell adhesion. The compound is a peptide having a sequence of the formula L1-A-L2-B-L3...
|
|
WO/2003/012127A2 |
A method for measuring heterodimerization of HIV RT, which comprises the steps of:a) providing a first solution comprising p66 subunit homodimers in the presence of a dissociation agent; b) contacting the first solution with p51 RT subun...
|
|
WO/2003/006070A2 |
The present invention relates to improved chelator conjugates of formula (II) with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal?99m¿Tc, a...
|
|
WO/2003/002730A2 |
The invention concerns a peptide coupled to at least a fluorogenic or colorogenic reporter molecule, characterised in that it contains at least a sequence of amino acids capable of being cleaved by calpain 3. The invention also concerns ...
|
|
WO/2002/083916A2 |
|
|
WO/2002/083928A2 |
A novel gene (designated 158P3D2) and its encoded protein, and variants thereof, are described wherein l58P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Cons...
|
|
WO/2002/083180A1 |
This invention is directed to prodrugs that can be activated at the preferred site of action in order to selectively deliver the corresponding therapeutic parent drugs to target cells or to the target site. This invention will therefore ...
|
|
WO/2002/083917A2 |
A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Cons...
|
|
WO/2002/070703A2 |
The present invention relates generally to peptides, polypeptides or proteins having one or more amino acids or one or more amino acid sequences which exhibit color-facilitating properties, either on their own or following interaction wi...
|
|
WO1999064055A9 |
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the 5HT4 receptors, which are involved in gastrointestinal disorders. The multibinding compounds of this invention containing f...
|
|
WO/2002/045523A2 |
A method of enzymatically producing a protein hydrolysate from a protein substrate is described, wherein a proline-specific endoprotease or a composition containing a proline-specific endoprotease and optionally a subtilisin or a metallo...
|
|
WO/2002/045524A2 |
The present invention provides a polypeptide isolated from Aspergillus niger which has proline specific endoprotease activity.
|
|
WO/2002/012275A2 |
The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interact...
|
|
WO/2001/079242A2 |
A process is described for preparing a substrate for the transglycosylase enzymes of bacterial cell wall biosynthesis. The chemical synthesis makes available a sustainable and substantially pure source of supply of lipid II, including an...
|
|
WO1999063937A9 |
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...
|
|
WO1999064041A9 |
Disclosed are novel multi-binding compounds (agents) which bind to NMDA receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors, thereby modulating the biological processes and/...
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
